Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Ранг среди акций #5435
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the... AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Цена акции
$169.98
Последняя синхронизация: 2026-09-25
Рыночная капитализация
$2.64B
Изменение (1 день)
0.69%
Изменение (1 год)
16.30%
Страна
GB
Торговля AstraZeneca PLC (AZN)

Категория

Выручка компании AstraZeneca PLC (AZN)
Выручка на Jun 2026 TTM: $61.37B
Согласно последним финансовым отчетам AstraZeneca PLC, текущая выручка компании (TTM) составляет $61.37B. В 2024 году компания получила выручку $54.07B больше, чем выручке в 2023 году, которая составила $45.81B. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки AstraZeneca PLC с 2000 по 2026
Выручка на конец каждого года
Год Выручка Изменить
2026 (TTM) $61.37B 4.47%
2025 $58.74B 8.63%
2024 $54.07B 18.03%
2023 $45.81B 3.29%
2022 $44.35B 18.53%
2021 $37.42B 40.58%
2020 $26.62B 9.16%
2019 $24.38B 10.38%
2018 $22.09B -1.67%
2017 $22.47B -2.33%
2016 $23.00B -6.90%
2015 $24.71B -6.93%
2014 $26.55B 2.87%
2013 $25.81B -7.75%
2012 $27.97B -16.72%
2011 $33.59B 0.97%
2010 $33.27B 1.42%
2009 $32.80B 3.81%
2008 $31.60B 6.91%
2007 $29.56B 11.65%
2006 $26.48B 10.54%
2005 $23.95B 11.78%
2004 $21.43B 13.67%
2003 $18.85B 5.65%
2002 $17.84B 8.26%
2001 $16.48B -9.03%
2000 $18.12B 0.00%
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
$79.67B 29.82%
US
$97.93B 59.58%
US
$64.39B 4.92%
US
$77.52B 26.32%
CH
$66.40B 8.20%
US